BioSpace News Archive

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”) today announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose low-density lipoprotein cholesterol (“LDL-C”) is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Blue Water Vaccines Inc. today announced that it has changed its corporate name to Blue Water Biotech, Inc.

Aevitas Therapeutics, Inc. today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new positive data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients.

GRI Bio, Inc. today announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla V. Simpson, M.Sc. to the Company’s Board of Directors.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.

Xenon Pharmaceuticals Inc. today announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced its new CORI™ Digital Tensioner - a purpose built device that lets surgeons measure the ligament tension in a knee prior to cutting bone.

BIORCHESTRA, a biotherapeutics company focused on rare and degenerative diseases within the Central Nervous System (CNS), today announced significant progress in its lead drug program – BMD-001.

Empatica today announced the launch of Empatica Actigraphy, a powerful new addition to the company’s FDA-cleared Empatica Health Monitoring Platform, offering a new set of digital biomarkers for monitoring sleep and physical activity along with the capability to collect data continuously for up to 14 days on a single charge.